Cargando…

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Oncogenic driver mutations have implications that extend beyond cancer cells themselves. Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti-tumour immunity, with important consequences for therapy response and resistance. We provide an overview of how mutant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watterson, Alex, Coelho, Matthew A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979509/ https://www.ncbi.nlm.nih.gov/pubmed/36864508 http://dx.doi.org/10.1186/s12964-023-01063-x

Ejemplares similares

Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target
por: Zhou, Junzhi, et al.
Publicado: (2023)

ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019)

KRAS drives immune evasion in a genetic model of pancreatic cancer
por: Ischenko, Irene, et al.
Publicado: (2021)

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
por: Prodeus, Aaron, et al.
Publicado: (2015)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion
por: Zhang, Yanyan, et al.
Publicado: (2022)

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
por: Song, Moo-Kon, et al.
Publicado: (2019)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation
por: Shang, Man, et al.
Publicado: (2021)

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
por: Ricklefs, Franz L., et al.
Publicado: (2018)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
por: Cen, Bo, et al.
Publicado: (2021)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches
por: Klein, Katherine, et al.
Publicado: (2020)

Correction for Zhou et al., Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target
Publicado: (2023)

PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination
por: Yu, Xinfang, et al.
Publicado: (2023)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
por: Kok, Victor C.
Publicado: (2020)

Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion
por: Huang, Hsiang‐Chi, et al.
Publicado: (2023)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
por: Hsu, Jung-Mao, et al.
Publicado: (2018)

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
por: Dong, Peixin, et al.
Publicado: (2018)

KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion
por: Sabe, Hisataka
Publicado: (2023)

β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
por: Du, Linyong, et al.
Publicado: (2020)

Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
por: Timaner, Michael, et al.
Publicado: (2019)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
por: Vannini, Andrea, et al.
Publicado: (2019)

Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion
por: Lin, Jichun, et al.
Publicado: (2023)

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment
por: Zhang, Feng, et al.
Publicado: (2022)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion
por: Gan, Li-Lian, et al.
Publicado: (2020)

DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
por: Chen, Baiwen, et al.
Publicado: (2022)

TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1
por: Li, Jinxin, et al.
Publicado: (2023)

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
por: Zhu, Qiang, et al.
Publicado: (2023)

Vascular Immune Evasion of Mesenchymal Glioblastoma Is Mediated by Interaction and Regulation of VE-Cadherin on PD-L1
por: Luo, Jing, et al.
Publicado: (2023)

Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes
por: Wang, Jinfeng, et al.
Publicado: (2023)

Immune evasion mechanisms and therapeutic strategies in gastric cancer
por: Ma, En-Si, et al.
Publicado: (2022)

Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
por: Lau, Poyee, et al.
Publicado: (2022)

LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression
por: Wu, Rongshou, et al.
Publicado: (2023)

Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer
por: Liu, Huashan, et al.
Publicado: (2023)

Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance
por: Deng, Yalan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4pghq6m6rvnoijc5a2d6ftmo76